

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 November 2006 (16.11.2006)

PCT

(10) International Publication Number
WO 2006/120434 A1

(51) International Patent Classification:

C12N 5/00 (2006.01) *C07K 16/28* (2006.01)
C12N 5/06 (2006.01) *G01N 33/53* (2006.01)
C07K 16/18 (2006.01) *G01N 33/569* (2006.01)

(21) International Application Number:

PCT/GB2006/001701

(22) International Filing Date: 10 May 2006 (10.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0509500.5 10 May 2005 (10.05.2005) GB

(71) Applicant (for all designated States except US): **RE-VEALCYTE** [GB/GB]; 21 Wilson Street, London EC2M 2TD (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **LEVICAR, Natasa** [SI/GB]; 30 elgin Crescent, London W11 2JR (GB).

(74) Agent: **FRANK B. DEHN & CO.**; St. Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF FETAL CELL ENRICHMENT

(57) Abstract: The present invention provides a method of enriching fetal cells in a maternal blood sample wherein cells which are CD34⁺ and capable of adhering to a solid support are selected, an analysable sample of fetal cells obtainable by the methods of the invention and a kit for use in the methods of the invention. There is also provided a method of fetal gender determination and a method of diagnosing a fetal genetic abnormality.



WO 2006/120434 A1

85541.214

Method of fetal cell enrichment

5 The present invention relates to a method of
enriching fetal cells in a maternal blood sample and to
a method of obtaining an analysable sample of fetal
cells. The sample obtained by the methods of the
present invention is particularly useful for non-
10 invasive fetal diagnosis and gender determination.

 There is a great demand for non-invasive fetal
diagnosis and gender determination. About 0.7% of all
live-born infants have a congenital abnormality
associated with a chromosomal defect and pre-natal
15 diagnosis of such defects is therefore of great
interest. Examples of chromosomal disorders which can
be detected (if present) in fetal cells include the
following Syndromes (Edwards, Patau, Downs, DiGeorge,
Wolf-Hirschorn, Cri du chat) and various conditions
20 caused by microdeletions.

 Current procedures for pre-natal fetal diagnosis
include amniocentesis and chorionic villus sampling.
Amniocentesis involves insertion of a needle through the
abdomen of the pregnant female into the uterus and
25 withdrawal of amniotic fluid from the sac surrounding
the fetus. Chorionic villus sampling (CVS) is performed
by inserting a catheter or needle into the placenta and
removing a small tissue sample. These procedures are
invasive and consequently cause discomfort to the mother
and carry a risk, particularly to the fetus. The risk of
30 fetal loss ranges from about 0.5% to 1% but may be as
high as 2%. Some studies indicate that CVS may cause
defects in the infant's fingers and toes. Amniocentesis
is performed during or after the 15th week of pregnancy
and CVS between the 10th and 12th weeks to minimise the
35 risk for the fetus. It would be preferable to have a

method which could be performed at an earlier stage of pregnancy. The cost of these procedures is also considerable. There is thus a need to develop non-invasive alternative methods. The analysis of fetal
5 cells from peripheral maternal blood represents a non-invasive method.

A variety of fetal cells (e.g. erythroblasts, lymphocytes) enter the maternal blood stream during pregnancy in small numbers and the presence of fetal
10 cells in maternal peripheral blood has been determined by many studies. However, the frequency of fetal cells in normal maternal peripheral blood is usually very low, ranging from $1:10^5$ to $1:10^9$. This frequency is too low to allow direct analysis of the fetal cells.

15 Indirect analysis can be carried out using DNA techniques such as polymerase chain reaction (PCR) amplification of fetal DNA. For example, PCR can be used to test for the presence in a maternal blood sample of a gene that is uniquely paternally inherited such as the
20 sry gene (located on the Y chromosome) or, if the mother is rhesus negative, the rhesus gene. However, because this approach is indirect it is not suitable for all types of desired applications, e.g. it can not be used for the diagnosis of fetal chromosomal disorders such as
25 aneuploidies in individual cells of fetal origin.

By contrast, direct methods allow the detection of a genetic disorder as well as determination of the gender in individual cells.

Direct analysis of fetal cells requires enrichment
30 of the maternal blood sample for fetal cells to obtain an analysable sample. A variety of methods have been tried in the past.

Many groups have attempted to expand fetal cells such as fetal erythroid progenitors or fetal
35 haemopoietic progenitors through culture (e.g. Chen et al., 1998, Manotaya et al., 2002). However, culture

methods had little success, especially in detecting fetal cells in maternal blood before 16 weeks gestation. Furthermore, culture methods are time consuming as 2-4 weeks of incubation are required before the fetal cells can be analysed. There is also a small chance that the genotype of the fetal cells might undergo changes as the cells go through repeated cycles of cell division during the culture step.

Other methods involve the use of antibodies that bind to fetal cells. The antibodies can be immobilised (Mueller et al., 1990, "Isolation of fetal trophoblasts cells from peripheral blood of pregnant women" The Lancet 336: 197-200) or labeled with binding moieties which allow sorting of labeled and unlabelled cells (e.g. Herzenberg et al., 1979 "Fetal cells in the blood of pregnant women: detection and enrichment by fluorescence-activated cell sorting", Proc. Natl. Acad. Sci (USA) 76:1453-1455).

The cluster differentiation (CD) antigens are a group of markers which are commonly targeted with specific monoclonal antibodies to isolate cells which carry a particular CD antigen (e.g. Bianchi et al., 1996 Proc. Natl. Acad. Sci (USA) 93: 705-708). This method involves incubation of the cells with a suitable monoclonal antibody labeled e.g. with a fluorescent dye or paramagnetic beads, followed by separation of antibody-bound cells from free cells using fluorescence-activated cell sorting or magnetically activated cell sorting technology respectively. The results obtained in these studies were unsatisfactory, not yielding a sufficient proportion of fetal cells for reliable analysis. This is because to date, no suitable cell marker which is unique to fetal cells and could be targeted with antibodies has been identified. The antibodies that have been tried to date, including those to CD antigens, target both fetal and maternal cells.

The ratios of maternal cells to fetal cells obtained with these antibodies are unsatisfactory, with samples containing such low proportions of fetal cells that they are not suitable for reliable analysis.

5 There is thus a need for a method of obtaining a sample that contains an analysable concentration of fetal cells. The present inventors have unexpectedly found that by isolating the CD34⁺ population of cells from maternal blood and selecting those cells which are
10 capable of adhering to a solid support, a significant and clinically useful proportion of fetal cells can be obtained. The solid support should preferably be transparent and have good optical properties for microscopic inspection. Preferably the solid support
15 has or consists of a glass or plastic surface. More preferably, the solid support is tissue culture grade plastic. Suitable culture grade plastic vessels are those manufactured by Corning Incorporated, New York, USA. The solid support may be coated with a suitable
20 substance such as protein, e.g. collagen or fibronectin, glycosaminoglycans, e.g. heparan sulphate or hyaluronic acid or complex carbohydrates, only coatings which do not significantly encourage non-fetal cells from binding are contemplated by the present invention.

25 The fetal cells which are enriched according to this method are preferably mononuclear, small (approximate diameter of 10 microns) with lymphocyte-like morphology and having a high nucleus: cytoplasm ratio.

30 Thus in one aspect, there is provided a method of enriching fetal cells in a maternal blood sample wherein cells which are CD34⁺ and capable of adhering to a solid support are selected.

35 The invention further provides a method of preparing a cell sample which is enriched for fetal cells which method comprises subjecting a maternal blood

sample to a procedure which selects those cells which are CD34⁺ and capable of adhering to a solid support.

Alternatively viewed, the invention provides a method of obtaining an analysable sample of fetal cells from a maternal blood sample, said method comprising:

a) enrichment of the sample for CD34⁺ cells; and

b) contacting the sample with a solid support and harvesting the cells which adhere to said solid support.

These two steps may be performed in either order, preferably step b) is performed on the product of step (a) and thus reference to 'the sample' in step b) and generally throughout the specification (unless otherwise clear from the context) includes reference to a fraction of the starting sample which has already been subjected to an enrichment or other step, typically to select CD34⁺ cells.

Alternatively viewed, the invention provides a method of enriching fetal cells in a maternal blood sample, said method comprising, in any order:

a) enrichment of the sample for CD34⁺ cells; and

b) contacting the sample with a solid support and harvesting the cells which adhere to said solid support.

'Enrichment' of a sample for cells of a certain type or having certain properties refers to an increase in the concentration and/or the proportion of cells of that type relative to starting levels in the sample. In the present context enrichment preferably refers to an increase in the proportion of target cells relative to non-target cells in the sample before and after the enrichment process step(s). Clearly enrichment may be performed by a step which removes non-target cells or other components from the sample, i.e. by way of negative selection, or more preferably a positive selection step is performed which targets the fetal cells of interest.

The method of the invention is preferably carried but by first obtaining cells which are CD34⁺ and then selecting an adherent sub-population thereof. However, methods in which non-adherent cells are removed first and a subpopulation of the adherent cells which is CD34⁺ is subsequently selected are also contemplated by the inventor.

Methods of enrichment for cells exhibiting particular cell surface markers such as CD34 are well known in the art. Methods will preferably involve an affinity ligand to CD34.

The affinity ligand is preferably an antibody. Both polyclonal and monoclonal antibodies can be used, monoclonal antibodies being preferred. The affinity ligand must bind, attach to or complex with the target marker (typically CD34 or a marker which is co-expressed with CD34) in a manner that ensures that the ligand and the cell possessing the target marker can be separated from ligand-free cells.

Preferably, a selectable label which can bind to the antibody is contacted with the sample prior to, simultaneously with, or after contacting the sample with the antibody. The label can consist e.g. of magnetic beads or a fluorescent dye.

Conveniently, the antibodies may be conjugated with markers, such as magnetic beads, which allow for direct separation, biotin, which can be removed with avidin or streptavidin bound to a support, fluorochromes, which can be used with a fluorescence activated cell sorter, or the like, to allow for ease of separation of the particular cell type. Preferably the technique employed is not unduly detrimental to the integrity of the cells, it being preferred that the majority of the intracellular components, in particular the nucleic acid, remain within the cells.

Procedures for separation may include magnetic separation if magnetic beads are used, affinity chromatography, cytotoxic agents joined to the antibody or used in conjunction with said antibody, e.g., complement and cytotoxins, and "panning" with antibody attached to a solid matrix, e.g., plate, or other convenient technique. Techniques providing accurate separation include fluorescence activated cell sorters, which can have varying degrees of sophistication, e.g.,

a plurality of colour channels, low angle and obtuse light scattering detecting channels, impedance channels, etc.

The methods of the invention result in enrichment of cells which are capable of adhering to certain solid supports, clearly one simple way of ensuring that the cells have this capability is by selecting the sub-population which is in fact adherent. Adherence, can be defined as being able to resist vigorous washing without detaching from the solid support. Vigorous washing may comprise immersion with manual rinsing actions. Some cells inevitably may be lost in the washing step but in general ability to adhere through this washing step will result in significant enrichment of fetal cells.

In a preferred embodiment, adherent cells are selected in the following manner. The cell sample is contacted with the solid support and incubated for a minimum of 1 or 2 hours and for up to 18 hours, preferably for about 2-3 hours at a temperature range of 20-38°C, preferably 35-38°C, even more preferably at 37°C. Most preferably, the incubation is carried out at 37°C for about 2 hours. Cells which adhere to the solid support are then harvested by washing off any non-adherent cells. The washing step can be carried out with any suitable buffer or cell culture medium. A

preferred wash solution is HBSS (Hanks Balanced salt solution) but other suitable media are known to the person skilled in the art. Preferably, the solution is water based and isotonic. The washing step simply involves immersion of the solid support in the wash solution followed by one or more thorough rinsing actions. Preferably, at least two, more preferably three vigorous washes are performed to remove as many of the non-adherent cells as possible.

10

The sample on which the method of the invention is performed is usually a sample of peripheral blood from a pregnant mammal. The method of the invention can be used on its own or in combination with other procedures. The term "maternal blood sample" encompasses thus a variety of samples, including a sample which has been taken from the maternal blood stream without further modification and a sample which has undergone one or more processing steps. Preferably, the sample consists of peripheral blood, i.e. blood found in the circulation vasculature. More preferably, the sample has been processed to remove unwanted non-cellular material from the sample. Thus "blood sample" also encompasses fractions and partially purified parts of total blood, in particular fractions which are enriched for dendritic cells or lymphocytes.

25

In a preferred embodiment the methods of the invention are carried out on the mononuclear fraction of the maternal blood sample. The skilled man is well aware of way in which to obtain the mononuclear fraction. For example, mononuclear cells can be separated from other components of peripheral blood by centrifugation, preferably density gradient centrifugation and most preferably discontinuous density gradient centrifugation. Preferably the mononuclear

35

fraction of the blood sample is separated using a Lymphoprep™ (Axis Shield) density gradient. Thus preferred methods of the invention comprise a preliminary step in which the sample is enriched for
5 mononuclear cells. The mononuclear fraction will include fetal cells as well as the maternal lymphocytes. Mature maternal red blood cells are of higher density and will be entirely or largely excluded.

The method of the present invention can be carried
10 out on a blood sample from any pregnant mammal. Preferably, the mammal is a human, equine or bovine mammal, most preferably a human. The maternal blood sample may be taken at any time after 7 weeks during pregnancy, preferably between weeks 10 and 20. The
15 blood sample may be as little as a finger prick droplet, but is preferably at least 1 ml, more preferably at least 5 ml, e.g. 10 ml or 20 ml, but higher volumes are also suitable. The method of the invention is preferably carried out on fresh samples, i.e. within 45-
20 75 min e.g. 1 hour after collection of the blood sample. However, processing may also be delayed until several hours after collection. The sample is preferably stored at 4°C and can be stored conveniently in this way for up to 18 hours.

25 Once a sample of cells has been obtained, this may be dried and fixed on a solid support and stored at -20°C for up to several weeks.

By using the method of the present invention, the inventor was able to obtain samples containing up to 10-
30 30% fetal cells. This level of enrichment of fetal cells has not previously been described. Thus, in another aspect the invention provides an analysable sample of fetal cells obtained from peripheral maternal blood comprising at least 10% of fetal cells.

35 Preferably, the sample comprises at least 15 or 20% of fetal cells, e.g. 10-30%, more preferably at least 25%

or 30%. In a further aspect the invention provides a cell sample which comprises 10-30% fetal cells and 90-70% maternal cells. It being appreciated that such a cell sample has a single source and is not provided simply by placing in admixture a maternal and a fetal cell sample.

In another aspect there is provided a kit for use in the methods of the invention comprising

- a) an affinity ligand to CD^{34} ; and
- b) a solid support

Optionally, the kit also comprises a suitable wash solution such as a buffer, e.g. HBSS. Suitable ligands and supports are described above.

The term "selection" as used herein should be understood to mean either positive or negative selection. Positive selection refers to retaining or collecting the desired cell population and negative selection refers to removing the undesired cell population.

By "analysable sample" is meant a sample which contains a sufficient number of fetal cells to allow direct analysis of the fetal cells such as, for example, by FISH analysis. Preferably, the number and proportion of fetal cells in the analysable sample is sufficiently high to give clinically acceptable success rates.

"CD34⁺ cells" are those cells which express the cluster differentiation antigen 34 and thus have the CD34 glycoprotein on their cell surface. A CD34⁺ cell population or fraction is to be understood as referring to a population of cells which are predominantly CD34⁺. Preferably, the CD34⁺ population is substantially free of any CD34⁻ cells, e.g. comprising at least 80% CD34⁺ cells, more preferably at least 90% CD34⁺ cells, most preferably at least 95% or 98% CD34⁺ cells.

The method of the present invention is particularly suited to obtain an analysable sample of fetal cells for

non-invasive fetal diagnosis and gender determination. In further aspects the invention thus provides a method of fetal gender determination which method comprises subjecting a sample of maternal blood enriched for fetal cells as described above, and preferably obtained according to one of the methods described above, to a procedure which enables male and female cells to be distinguished. The cells will typically be distinguished at the chromosomal level, XX being differentiated from XY, e.g., by FISH.

The invention further provides a method of diagnosing a fetal genetic abnormality (i.e. any condition, whether inherited or not, for which undesirable phenotypic characteristics can be linked to a particular genotype), which method comprises contacting a sample of maternal blood enriched for fetal cells as described above, and preferably obtained according to one of the methods described above with an agent capable of distinguishing between genetically normal and genetically abnormal cells.

In a further aspect there is provided a method of enriching fetal cells in a maternal blood sample wherein cells which are CD34⁺ and capable of adhering to a solid support are selected as described herein, wherein said selected cells are subjected to genetic analysis. By "genetic analysis" is meant any analysis of the genetic material of the cells, including analysis of the number, shape and size of chromosomes, presence or absence of specific genes or nucleic acid sequences, and screening for any kinds of mutations such as deletions, insertions, point mutations and the like. Preferably, said genetic analysis includes screening for a fetal genetic abnormality. Said genetic analysis may also or alternatively include gender determination.

The sample of fetal cells that can be obtained with the method of the present invention is suitable for both

direct and indirect analysis. Examples of methods of analysis which can be carried out on the samples obtainable by the method of the invention or more generally in conjunction with the methods of the present invention are given below but it should be understood that the skilled person will be aware of other methods of analysis which can be carried out on the samples of the invention. Direct methods of analysis are preferred and include FISH (fluorescence in situ hybridisation). For example, probes which bind the X and Y chromosomes respectively can be used to determine the gender of the fetus. Multicolor FISH can be used to detect chromosomal abnormalities in fetal cells. Probes specific for each individual chromosome each labelled with a different colour are available and these can be used to analyse the number and shape of the chromosomes present in the fetal cells. Suitable probes are described for example in Griffin, D.K., Handyside, A.H., Harper, J. et al. (1994) Clinical experience with preimplantation diagnosis of sex by dual fluorescent in situ hybridisation. *J. Assist. Reprod. Genet.*, 11, 132-143; Munné, S., Tang, Y.X., Grifo, J. et al. (1994) Sex determination of human embryos using the polymerase chain reaction and confirmation by fluorescence in situ hybridization. *Fertil. Steril.*, 61, 111-117; Staessen, C., Van Assche, E., Joris, H. et al. (1999) Clinical experience of sex determination by fluorescent in situ hybridization for preimplantation genetic diagnosis. *Mol. Hum. Reprod.*, 5, 382-389.

A different method of gender determination which may be used in addition or in the alternative is PCR amplification of the male-specific *sry* gene. The prior art describes suitable primers, e.g. Erdal and Barlas, Turkish Journal of Medical Science 30, 2000, pages 501-503. Suitable primers are also commercially available, e.g. from Fisher Life Science Catalog or Maxim Biotech.

A variety of different probes/visualisation methods may be used to detect the various genetic abnormalities which involve trisomy or large deletions. For Syndromes caused by microdeletions specific probes are preferred.

5 Suitable methods for carrying out an analysis of the fetal cells are known to the skilled person and are described e.g. in the following references which also detail particular genetic disorders.

10 Boghosian-Sell L et al. Molecular mapping of the Edwards syndrome phenotype to two noncontiguous regions on chromosome 18. Am J Hum Genet 1994; 476-83.

15 Helali N et al. A case of duplications 13q32-->qter and deletion of 18p11.32-->pter with mild phenotype: Patau syndrome and duplications of 13q revisited. J Med Genet 1996; 33: 600-2.

Witters I et al. Rapid prenatal diagnosis of trisomy 21 in 5049 consecutive uncultured amniotic fluid samples by fluorescence in situ hybridisation (FISH) Prenat Diagn 2002; 22: 29-33.

20 Oskarasdottir S et al. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child 2004; 89: 148-51.

25 Marinescu RC et al. FISH analysis of terminal deletions in patients diagnosed with cri-du-chat syndrome. Clin Genet 1999; 56: 282-8.

In further applications, a viable enriched sample may be induced to divide and arrest in metaphase of the cell cycle in order to obtain full cytogenic analysis.

30 Further the enriched samples may be suitable when screening blood to be used for transfusions when nucleated white cell transfusions are required. The samples may also be used when screening dendritic cell and donor lymphocyte infusions as these can also result in graft-versus-host disease. Bone marrow and umbilical
35 cord blood may also be used in transplants to treat haematological deficiency conditions and the same

enrichment methods may be performed on such samples in order to perform phenotypic or more preferably genotypic analysis of fetal cells within the sample.

5 The invention will be further described in the following non-limiting Examples.

Example 1

Blood samples were taken from peripheral blood of pregnant women at termination of pregnancy and from mothers of sons. The mononuclear cell fraction was separated from the whole sample by density gradient centrifugation through Lymphoprep™ and the CD³⁴ positive cell fraction was then separated from the mononuclear cells using MiniMACS technology (Miltenyi Biotech). For this, cells were first labelled with anti-CD³⁴ monoclonal antibody and then with paramagnetic micro beads. The labelled cells were loaded onto a column held in a magnet, the unlabelled cells were eluted and then the labelled cells were released by removing the column from the magnet. The purified CD³⁴ positive cells were incubated on a glass or tissue culture plastic microscope slide at 37°C for at least 2 hours. The non-adherent cells were removed by washing with Hanks' Balanced Salt Solution (HBSS). The slides were air-dried and fixed in methanol: glacial acetic acid for 30 minutes. The slides may then be stored for several weeks prior to analysis by wrapping in foil and freezing at -20°C.

Fluorescence in situ hybridisation (FISH)

Slides that had been stored frozen were brought to room temperature before they were unwrapped. The X/Y dual label probe was warmed to 37°C. The slides were dehydrated through an ethanol series (75%, 95%, 100% - 1 minute in each) and then air dried. 5µl of the probe was placed in the centre of the cells on the slide. The preparation was covered with a small coverslip which was sealed around the edges with rubber solution. The slide was placed on a hotplate at 73°C for 5 minutes then in a humidified chamber at 37°C overnight. The next morning, the rubber solution and coverslip were removed and the

slide mounted in DAPI 4',6-Diamidino-2-phenylindole antifade solution.

Analysis of fetal cells in the enrichment sample

5 The slides were viewed on an Olympus fluorescence microscope attached to a MacIntosh computer. At least 50 cells per sample were scored by the eye. The Y chromosome probe was stained with SpectrumGreen and the X chromosome probe with SpectrumOrange. Thus, male
10 cells will yield one green and one red signal; female cells will have two red signals. In the samples tested, 10-27% of the cells contained the male Y chromosome

Example 2

15 Table 1 below lists some chromosomal disorders which can be detected in fetal cells enriched according to the methods of the present invention.

Table 1

Syndrome	Cytogenetic and phenotypic features
Edwards	Trisomy 18; 1/3000 births; mental retardation; dysmorphism; survival < 1 year
Patau	Trisomy 13; 1/5000; motor/mental retardation; survival < 6 months
Downs	Trisomy 21; mongolism
DiGeorge	Deletion 22q11; cardiac malformation; endocrine/immune anomalies; facial attributes
Wolf-Hirschorn	Deletion 4p; 1/50000 births; midline fusion defects; 34% mortality in 2 years
Cri du chat	Deletion 5p; mental handicap; characteristic cry
	Various chromosomes; dysmorphic features

A variety of different probes/visualisation methods may be used to detect the various conditions which involve trisomy or large deletions. For Syndromes caused by microdeletions specific probes are required.

5 Suitable methods for carrying out an analysis of the fetal cells are known to the skilled person and are described e.g. in the following references which also detail particular genetic disorders.

10 Boghosian-Sell L et al. Molecular mapping of the Edwards syndrome phenotype to two noncontiguous regions on chromosome 18. Am J Hum Genet 1994; 476-83.

 Helali N et al. A case of duplications 13q32-->qter and deletion of 18p11.32-->pter with mild phenotype: Patau syndrome and duplications of 13q
15 revisited. J Med Genet 1996; 33: 600-2.

 Witters I et al. Rapid prenatal diagnosis of trisomy 21 in 5049 consecutive uncultured amniotic fluid samples by fluorescence in situ hybridisation (FISH) Prenat Diagn 2002; 22: 29-33.

20 Oskarasdottir S et al. Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden. Arch Dis Child 2004; 89: 148-51.

 Marinescu RC et al. FISH analysis of terminal deletions in patients diagnosed with cri-du-chat
25 syndrome. Clin Genet 1999; 56: 282-8.

1. A method of enriching fetal cells in a maternal blood sample wherein cells which are CD34⁺ and capable of adhering to a solid support are selected.

5 2. A method according to claim 1, said method comprising, in any order:

a) enrichment of the sample for CD34⁺ cells; and

b) contacting the sample with a solid support and harvesting the cells which adhere to said solid support.

3. A method according to claim 2, wherein step (b) is performed on the product of step (a).

15 4. A method according to claim 2, wherein step (a) is performed on the product of step (b).

5. A method according to any one of claims 1-4 wherein an affinity ligand to CD34 is used.

20 6. A method according to claim 5 wherein said affinity ligand is an antibody.

7. A method according to claim 5 or 6 wherein a selectable label which can bind to said affinity ligand is contacted with the sample prior to, simultaneously with, or after contacting the sample with said affinity ligand.

30 8. A method according to claim 7, wherein said selectable label consist of magnetic beads or a fluorescent dye.

9. A method according to any one of claims 5 to 8 wherein said affinity ligand is conjugated with a marker such as magnetic beads, biotin or fluorochromes.

5 10. A method according to any one of claims 1-9 wherein selection of adherent cells comprises contacting the sample with a solid support and incubating for 1 to 18 hours at a temperature range of 20-38°C.

10 11. A method according to any one of claims 1-10 wherein the method is carried out on the mononuclear fraction of the maternal blood sample.

12. An analysable sample of fetal cells obtained
15 from peripheral maternal blood comprising at least 10% fetal cells.

13. An analysable sample of fetal cells obtainable by a method according to any one of claims 1-11.

20

14. An analysable sample of fetal cells according to claim 12 or 13 comprising at least 20% fetal cells.

15. A kit for use in the methods of any one of
25 claims 1 to 11 comprising
a) an affinity ligand to CD³⁴; and
b) a solid support.

16. A method of fetal gender determination, which
30 method comprises subjecting a sample according to any one of claims 12-14 to a procedure which enables male and female cells to be distinguished.

17. A method of diagnosing a fetal genetic abnormality, which method comprises contacting a sample according to any one of claims 12-14 with an agent
5 capable of distinguishing between genetically normal and genetically abnormal cells.

18. A method according to claim 16 or 17 wherein fluorescence *in situ* hybridisation is used.
10

19. A method of preparing a cell sample which is enriched for fetal cells which method comprises subjecting a maternal blood sample to a procedure which selects those cells which are CD34⁺ and capable of
15 adhering to a solid support.

20. A method according to any one of claims 1-11, wherein said selected cells are subjected to genetic analysis.
20

21. A method according to claim 20, wherein said genetic analysis includes gender determination.

22. A method according to claim 20 or 21, wherein
25 said genetic analysis includes screening for a fetal genetic abnormality.

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/001701

A. CLASSIFICATION OF SUBJECT MATTER INV. C12N5/00 C12N5/06 C07K16/18 C07K16/28 G01N33/53 G01N33/569		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12N C07K G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	LITTLE M-T ET AL: "FREQUENCY OF FETAL CELLS IN SORTED SUBPOPULATIONS OF NUCLEATED ERYTHROID AND CD34+ HEMATOPOIETIC PROGENITOR CELLS FROM MATERNAL PERIPHERAL BLOOD" BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 89, no. 7, 1 April 1997 (1997-04-01), pages 2347-2358, XP001015906 ISSN: 0006-4971 page 2348 page 2353, column 1 tables 5,6 ----- -/--	1-22
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 18 July 2006		Date of mailing of the international search report 02/08/2006
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Bayer, M

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/001701

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUETTA E ET AL: "Hematopoietic progenitor cells as targets for non-invasive prenatal diagnosis: Detection of fetal CD34+ cells and assessment of post-delivery persistence in the maternal circulation." BLOOD CELLS MOLECULES AND DISEASES, vol. 30, no. 1, January 2003 (2003-01), pages 13-21, XP002390566 ISSN: 1079-9796 page 14, column 2 - page 15, column 1 tables 1,2 figure 2 -----	1-22
X	COATA GIULIANA ET AL: "Prenatal diagnosis of genetic abnormalities using fetal CD34+ stem cells in maternal circulation and evidence they do not affect diagnosis in later pregnancies" STEM CELLS (MIAMISBURG), vol. 19, no. 6, 2001, pages 534-542, XP002390567 ISSN: 1066-5099 page 535, column 2, paragraph 2 page 536, column 1, paragraph 3 page 536, column 2, paragraph 2 page 537; table 1 table 2 -----	1
X	CAMPAGNOLI CESARE ET AL: "Expandability of haemopoietic progenitors in first trimester fetal and maternal blood: implications for non-invasive prenatal diagnosis." PRENATAL DIAGNOSIS. JUN 2002, vol. 22, no. 6, June 2002 (2002-06), pages 463-469, XP002390568 ISSN: 0197-3851 page 464 figure 3 -----	1
X	WO 94/25873 A (CELLPRO, INCORPORATED; HALL, JEFF, M; ADAMS, SHARON, L) 10 November 1994 (1994-11-10) page 19, paragraph 3 examples 14,17 claims 1,12,20 -----	1
P,X	WO 2005/123779 A (THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS; SHARMA, ARUN; ELI) 29 December 2005 (2005-12-29) examples 9-17 claims 8-14 figure 2 -----	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/001701

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9425873	A	10-11-1994	AU 6773994 A	21-11-1994
WO 2005123779	A	29-12-2005	NONE	